Swiss pharma giant Novartis on Thursday reported more than 40% growth in profit in the second quarter, primarily driven by strong sales for a few key drugs. Novartis also raised its full-year core operating income guidance. Net income for the second quarter was $3.2 billion, up from $2.2 billion in the same quarter a year ago. Operating income rose 43% to $4 billion from a year ago. Revenue for the quarter grew 9% to $12.5 billion. The company’s top two drugs – Entresto, which is used to treat patients with heart failure, and Cosentyx, for psoriasis and arthritis – raked in $1.9 billion and $1…